On December 23, 2024, Andrew Combs, Chief Chemistry Officer at Prelude Therapeutics Inc, purchased 63,075 shares of the company. Following this transaction, the insider now holds a total of 377,623 shares. The purchase was documented in an SEC Filing.
Prelude Therapeutics Inc (PRLD, Financial) is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key drivers of cancer cell growth, resistance, and survival. The company aims to improve the lives of patients with cancer through the development of novel therapeutics.
The insider's recent acquisition is part of a broader trend within the company. Over the past year, there have been three insider purchases and no insider sales, indicating a positive sentiment among the company's insiders.
On the day of the purchase, shares of Prelude Therapeutics Inc were trading at $1.36 each, resulting in a market cap of $73.747 million. This transaction reflects the insider's confidence in the company's potential and future prospects.
For more information on the insider's trading activity, visit Andrew Combs's profile on GuruFocus.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
